Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Cash Flow for Dividends: ¥-1,885 Mil (TTM As of Mar. 2026)


SHSE:600196 Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
78 GF Score
Price ¥23.12
GF Value ¥27.09
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends?

Shanghai Fosun Pharmaceutical (Group) Co SHSE:600196 +2.89% 78 Cash Flow for Dividends is ¥-1,885 Mil as of Mar. 2026. GuruFocus rates SHSE:600196 with a GF Score™ of 78/100 and a GF Value™ of ¥27.09 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Shanghai Fosun Pharmaceutical (Group) Co's cash flow for dividends for the three months ended in Mar. 2026 was ¥-242 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-1,885 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly payment of dividends declined from Sep. 2025 (¥-1,111 Mil) to Dec. 2025 (¥-236 Mil) but then increased from Dec. 2025 (¥-236 Mil) to Mar. 2026 (¥-242 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual payment of dividends declined from Dec. 2023 (¥-2,455 Mil) to Dec. 2024 (¥-2,059 Mil) and declined from Dec. 2024 (¥-2,059 Mil) to Dec. 2025 (¥-1,945 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Related Terms

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,913.96 -2,374.37 -2,455.17 -2,059.42 -1,944.64

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -301.82 -295.90 -1,110.98 -235.95 -242.36
SHSE:600196
78GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd SHSE:600196
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,885 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ¥-1,885 Mil mean?
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a Cash Flow for Dividends of ¥-1,885 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Dividends too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Cash Flow for Dividends is ¥-1,885 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Dividends compare to ZTS and UTHR?
Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Dividends of ¥-1,885 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Cash Flow for Dividends is ¥-1,885 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.09, compared to a current price of ¥23.12 — trading 14.7% below its estimated fair value. The current Cash Flow for Dividends is ¥-1,885 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 78/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current Cash Flow for Dividends is ¥-1,885 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of ¥23.12 is trading 14.7% below its estimated GF Value™ of ¥27.09. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for SHSE:600196:

  • Cash Flow for Dividends: ¥-1,885 Mil
  • GF Value™: ¥27.09 vs. price of ¥23.12 (14.7% below fair value)
  • GF Score™: 78/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
78GF Score

Get the complete analysis for SHSE:600196

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥23.12
Price
¥27.09
GF Value